Cargando…

Patient‐reported outcomes on empagliflozin treatment in glycogen storage disease type Ib: An international questionnaire study

In patients with glycogen storage disease type Ib (GSD Ib), quality of life is severely hampered by neutropenia and neutropenia‐associated symptoms. SGLT2 inhibitors are a new treatment option and have shown improved medical outcomes in more than 120 patients so far. The aim of this international qu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Grünert, Sarah C., Venema, Annieke, LaFreniere, Jamas, Schneider, Blair, Contreras, Enrique, Wortmann, Saskia B., Derks, Terry G. J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2023
Materias:	Research Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10159866/ https://www.ncbi.nlm.nih.gov/pubmed/37151361 http://dx.doi.org/10.1002/jmd2.12364

Ejemplares similares

Improved inflammatory bowel disease, wound healing and normal oxidative burst under treatment with empagliflozin in glycogen storage disease type Ib
por: Grünert, Sarah C., et al.
Publicado: (2020)

Two successful pregnancies and first use of empagliflozin during pregnancy in glycogen storage disease type Ib
por: Grünert, Sarah Catharina, et al.
Publicado: (2022)

Towards values‐based healthcare for inherited metabolic disorders: An overview of current practices for persons with liver glycogen storage disease and fatty acid oxidation disorders
por: Venema, Annieke, et al.
Publicado: (2022)

Crohn disease-like enterocolitis remission after empagliflozin treatment in a child with glycogen storage disease type Ib: a case report
por: Rossi, Alessandro, et al.
Publicado: (2021)

Untargeted metabolomic profiling in a patient with glycogen storage disease Ib receiving empagliflozin treatment
por: Tallis, Eran, et al.
Publicado: (2022)

A Prospective Study on Continuous Glucose Monitoring in Glycogen Storage Disease Type Ia: Toward Glycemic Targets
por: Rossi, Alessandro, et al.
Publicado: (2022)

The overall benefits of empagliflozin treatment in adult siblings with glycogen storage disease type Ib: one year experience
por: Bidiuk, Joanna, et al.
Publicado: (2022)

Repurposing of Empagliflozin as a Possible Treatment for Neutropenia and Inflammatory Bowel Disease in Glycogen Storage Disease Type Ib: A Case Report
por: Makrilakis, Konstantinos, et al.
Publicado: (2022)

Next-generation glycogen storage diseases
por: Derks, Terry G. J., et al.
Publicado: (2018)

Crohn-like disease long remission in a pediatric patient with glycogen storage disease type Ib treated with empagliflozin: a case report
por: Calia, Margherita, et al.
Publicado: (2023)

A retrospective study of eating and psychosocial problems in patients with hepatic glycogen storage diseases and idiopathic ketotic hypoglycemia: Towards a standard set of patient‐reported outcome measures
por: Venema, Annieke, et al.
Publicado: (2021)

Glycogen Storage Disease Ib and Severe Periodontal Destruction: A Case Report
por: Ma, Rui, et al.
Publicado: (2018)

Current understanding on pathogenesis and effective treatment of glycogen storage disease type Ib with empagliflozin: new insights coming from diabetes for its potential implications in other metabolic disorders
por: Maiorana, Arianna, et al.
Publicado: (2023)

Lipids in hepatic glycogen storage diseases: pathophysiology, monitoring of dietary management and future directions
por: Derks, Terry G. J., et al.
Publicado: (2015)

The natural history of glycogen storage disease type Ib in England: A multisite survey
por: Halligan, Rebecca, et al.
Publicado: (2021)

Liver transplantation in glycogen storage disease type Ib: The role of SGLT2 inhibitors
por: Murko, Simona, et al.
Publicado: (2023)

The Phenotypic and Genetic Spectrum of Glycogen Storage Disease Type VI
por: Grünert, Sarah Catharina, et al.
Publicado: (2021)

Favorable outcome of empagliflozin treatment in two pediatric glycogen storage disease type 1b patients
por: Hexner-Erlichman, Zufit, et al.
Publicado: (2022)

Novel SLC37A4 Mutations in Korean Patients With Glycogen Storage Disease Ib
por: Choi, Rihwa, et al.
Publicado: (2017)

Infectious and digestive complications in glycogen storage disease type Ib: Study of a French cohort
por: Wicker, Camille, et al.
Publicado: (2020)

Glycogen Storage Disease Type Ia: Current Management Options, Burden and Unmet Needs
por: Derks, Terry G. J., et al.
Publicado: (2021)

Mutation analysis of SLC37A4 in a patient with glycogen storage disease-type Ib
por: Zhang, Yamei, et al.
Publicado: (2019)

Clinical analysis and long-term treatment monitoring of 3 patients with glycogen storage disease type Ib
por: Du, Caiqi, et al.
Publicado: (2021)

A Novel Lipoprotein Lipase Mutation in an Infant With Glycogen Storage Disease Type-Ib and Severe Hypertriglyceridemia
por: Wang, Fengyu, et al.
Publicado: (2021)

Successful pregnancy in a woman with glycogen storage disease type 6
por: Grünert, Sarah Catharina, et al.
Publicado: (2021)

Understanding the role of SGLT2 inhibitors in glycogen storage disease type Ib: the experience of one UK centre
por: Halligan, Rebecca K., et al.
Publicado: (2022)

Three successful pregnancies in a patient with glycogen storage disease type 0
por: Grünert, Sarah C., et al.
Publicado: (2020)

Glycogen storage disease type Ia: Adult presentation with microcytic anemia and liver adenomas
por: Moest, Wouter, et al.
Publicado: (2018)

Clinical Remission of Severe Crohn’s Disease with Empagliflozin Monotherapy in a Pediatric Patient with Glycogen Storage Disease Type 1b
por: Collen, Lauren V., et al.
Publicado: (2023)

The potential of dietary treatment in patients with glycogen storage disease type IV
por: Derks, Terry G. J., et al.
Publicado: (2020)

Glycogen storage disease type Ia (GSDIa) but not Glycogen storage disease type Ib (GSDIb) is associated to an increased risk of metabolic syndrome: possible role of microsomal glucose 6-phosphate accumulation
por: Melis, Daniela, et al.
Publicado: (2015)

Finding balance between mature and immature neutrophils: The effects of empagliflozin in GSD‐Ib
por: Guerra, Fabiola, et al.
Publicado: (2023)

The multiple faces of urinary glucose tetrasaccharide as biomarker for patients with hepatic glycogen storage diseases
por: Heiner-Fokkema, M. Rebecca, et al.
Publicado: (2020)

Metabolic Profiling in Human Fibroblasts Enables Subtype Clustering in Glycogen Storage Disease
por: Hannibal, Luciana, et al.
Publicado: (2020)

Tuberculosis in Canada: 2017
por: LaFreniere, M, et al.
Publicado: (2019)

Impact of glycogen storage disease type I on adult daily life: a survey
por: Garbade, Sven F., et al.
Publicado: (2021)

Perspective on Nanofiber Electrochemical Sensors: Design of Relative Selectivity Experiments
por: Feeney, Stanley G., et al.
Publicado: (2021)

Elevated Plasma Vitamin B(12) in Patients with Hepatic Glycogen Storage Diseases
por: Hinkel, Julia, et al.
Publicado: (2020)

Glycogen storage diseases: An update
por: Gümüş, Ersin, et al.
Publicado: (2023)

Glycogen storage disease type III: diagnosis, genotype, management, clinical course and outcome
por: Sentner, Christiaan P., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_30nfjuni31a6o8apemgfs23im0